第十届董事会第十三次会议 2025 年 8 月 21 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－067 华润双鹤药业股份有限公司 第十届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、董事会会议召开情况 公司第十届董事会第十三次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 8 月 11 日以邮件方 式向全体董事发出，会议于 2025 年 8 月 21 日以现场及通讯方式召开。 出席会议的董事应到 11 名，亲自出席会议的董事 10 名。董事长陆文 超先生因工作原因委托董事赵骞先生出席会议，并授权对本次会议通 知中所列议题代行同意的表决权。会议由半数以上董事共同推选赵骞 先生主持。公司监事列席会议。公司董事会秘书刘驹先生列席会议。 二、董事会会议审议情况 详见上海证券交易所网站 www.sse.com.cn。 《2025 年半年度报告》 《 2025 年 半 年 度 报 告 摘 要 》 详 见 上 海 证 券 交 易 所 网 ...

Core Viewpoint - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.1 RMB per share (before tax) [1][2]. Summary by Sections Profit Distribution Plan - As of June 30, 2025, the company's undistributed profits amounted to 6,004,798,406.10 RMB [1]. - The proposed distribution is 1.00 RMB (before tax) for every 10 shares held, based on the total share capital registered on the dividend distribution date [1][2]. - The total amount of cash dividends cannot be determined until the actual number of shares entitled to participate in the distribution is known [1]. Decision-Making Process - The company's board of directors held the 13th meeting of the 10th board on August 21, 2025, where the profit distribution proposal was approved with 11 votes in favor and no opposition [2]. - The proposal aligns with the company's profit distribution policy as outlined in its articles of association [2]. - The supervisory board supports the proposal, stating it balances shareholder returns with the company's operational needs and sustainable development [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 公 告 （於香港註冊成立的有限公司） （股份代號：3320） 1 於2025年8月22日，華潤雙鶴公佈其截至2025年6月30日止六個月的半年度報告 （「華潤雙鶴未經審核財務資料」）。下表載列華潤雙鶴未經審核財務資料的主 要財務數據： | | 截至2025年 | 截至2024年 | | | --- | --- | --- | --- | | | 6月30日 | 12月31日 | 增加 | | | （人民幣） | （人民幣） | (%) | | | （未經審核） | （經審核） | | | 總資產 | 16,741,002,778.93 | 16,685,995,679.77 | 0.33 | | 截至6月30日止六個月 | | --- | | | 2025年 | 2024年 | 增加╱減少 | | --- | --- | --- | --- | | | （人民幣） | （人民幣） | (%) | | ...

Core Viewpoint - The company is actively implementing the "Quality Improvement and Efficiency Enhancement Return" action plan to enhance its investment value and protect investors' rights, with significant progress reported in various operational areas [1][7]. Action Plan Execution - The company has established a special working leadership group to oversee the action plan, ensuring a focus on quality, efficiency, and investment returns [1]. - A comprehensive approach has been adopted, involving multiple departments to drive high-quality development and enhance investment value [1]. Measures Implementation Effects Improvement of Operational Quality - The company is focusing on dual drivers of R&D innovation and external development to enhance core competitiveness, with increased R&D investment and a shift from "technology-oriented" to "value-oriented" product development [2]. - Smart factory initiatives have been launched, resulting in increased production capacity and labor productivity [2]. - The company is pursuing mergers and acquisitions in targeted segments, with three product agreements completed [2]. Accelerating New Quality Productivity - The company is advancing its innovation transformation, having completed the first phase of its R&D strategy and is now moving into deeper strategic phases [3]. - A total of 15 projects are in progress, with significant breakthroughs in innovative drug development, including the launch of a pediatric microtablet formulation and clinical approvals for several oncology drugs [3]. Enhancing Corporate Governance - The company is optimizing its governance structure and has initiated revisions to core regulations to align with new legal requirements [4]. - The board structure is being improved, with a focus on enhancing oversight and integrating sustainable development into strategic planning [4]. Strengthening Responsibility of Key Personnel - A responsibility mechanism has been implemented to align performance incentives with company results, ensuring accountability among management [5]. - The company has activated a stock incentive plan to motivate key personnel and align their interests with company performance [5]. Increasing Investor Returns - The company has established a comprehensive market value management system, with a total cash dividend and share buyback amounting to 1.4 billion yuan over the past three years, achieving a cash dividend ratio of 84% [6]. - A semi-annual dividend distribution has been initiated to enhance shareholder returns [6]. Enhancing Investor Communication - The company is expanding its investor relations communication channels, including hybrid shareholder meetings and various interactive sessions to engage with investors [6]. - Innovative information dissemination methods are being employed to improve transparency and investor understanding of company performance [6]. Conclusion - The company is committed to continuously evaluating and optimizing the "Quality Improvement and Efficiency Enhancement Return" action plan to ensure effective implementation and adapt to market changes [7].

第十届董事会十三次会议 2025 年 8 月 21 日 本次公司债券的规模为不超过人民币 30 亿元(含 30 亿元)，具体发 行规模由股东会授权董事会根据公司资金需求情况和发行时市场情况， 在上述范围内确定。 第十届董事会十三次会议 2025 年 8 月 21 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 华润双鹤药业股份有限公司(以下简称"公司")于 2025 年 8 月 21 日 召开第十届董事会第十三次会议，审议通过了公开发行公司债券相关事 项。本次公开发行公司债券(以下简称"本次公司债券")尚需提交公司股 东会审议并经中国证券监督管理委员会(以下简称"中国证监会")同意 注册后方可实施。现将本次公司债券具体情况说明如下： 一、关于公司符合发行公司债券条件的说明 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－069 华润双鹤药业股份有限公司 根据《公司法》《证券法》《公司债券发行与交易管理办法》和《上 海证券交易所公司债券上市规则》等相关法律、法规和规范性文件的规 定，经对照自查，董事会认 ...

Group 1 - The tenth meeting of the supervisory board was held on August 21, 2025, in accordance with the Company Law and the company's articles of association [1] - The supervisory board reviewed the 2025 semi-annual report and confirmed that the report's content and format comply with regulatory requirements, accurately reflecting the company's operational and financial status [1] - The profit distribution plan for the first half of 2025 considers reasonable returns for shareholders while ensuring the company's sustainable development [1] Group 2 - The company plans to issue corporate bonds with a total scale not exceeding RMB 3 billion, subject to shareholder approval [2] - The bonds will have a face value of RMB 100 each and will be issued at par, targeting professional investors as defined by relevant regulations [2][3] - The proposed bond term is up to 7 years, with the specific terms to be determined based on market conditions and company needs [2] Group 3 - The proceeds from the bond issuance will be used for repaying interest-bearing debts, supporting investments and acquisitions, and supplementing working capital [4] - The company has a good credit status over the past three years, and if it cannot repay the bonds, it will take measures such as not distributing profits to shareholders and deferring major capital expenditures [4] - The resolution for the bond issuance will remain valid until the expiration of the registration document issued by the China Securities Regulatory Commission [4]

Meeting Information - The second extraordinary general meeting of shareholders will be held on September 9, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1] - The on-site meeting will take place at 9:00 AM at the Ruichuang International Center, Beijing [1] - Online voting will be conducted through the Shanghai Stock Exchange's voting system on the same day [1][5] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system or in person [5] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [5] - Duplicate votes through different methods will be counted based on the first vote cast [5] Attendance and Registration - Only shareholders registered by the close of trading on September 3, 2025, are eligible to attend [6] - Registration for the meeting will occur on September 4, 2025, at the company's Securities and Legal Affairs Department [6] - Both natural and legal persons must provide appropriate identification and authorization documents for registration [6] Agenda Items - The meeting will review a proposal to authorize the board of directors to handle matters related to the public issuance of corporate bonds [3][4]

Core Viewpoint - China Resources Double Crane (华润双鹤) has announced the approval of a public bond issuance plan by its 13th meeting of the 10th Board of Directors, pending shareholder meeting approval and registration with the China Securities Regulatory Commission [1] Group 1 - The scale of the public bond issuance is set to be no more than RMB 3 billion (including 3 billion) [1] - The specific issuance scale will be determined by the Board of Directors based on the company's funding needs and market conditions at the time of issuance, within the authorized range by the shareholder meeting [1] - The raised funds, after deducting issuance costs, are intended for repaying interest-bearing liabilities, supporting investment and acquisitions, and supplementing working capital, among other legally permitted uses [1]

根据上海证券交易所发布的上市公司分行业信息披露指引《上市 公司自律监管指引第3号——行业信息披露之第六号——医药制造》 及《关于做好主板上市公司2025年半年度报告披露工作的重要提醒》 相关要求，现将公司2025年半年度主营业务分行业、分产品情况数据 披露如下： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－073 华润双鹤药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 单位：元 币种：人民币 华润双鹤药业股份有限公司 董 事 会 2025 年 8 月 23 日 注：公司从战略定位角度出发对华润紫竹等部分产品的划分进行 细化调整，重述上年同期数据。 本公告之经营数据未经审计，提醒投资者审慎使用上述数据。 特此公告。 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 | 营业收入比 上年同期增 | 营业成 ...

第十届董事会第十三次会议 2025 年 8 月 21 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－070 华润双鹤药业股份有限公司 关于 2025 年度"提质增效重回报"行动方案的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 为进一步提高上市公司质量，提升公司投资价值，保护投资者合 法权益，积极响应并践行"以投资者为本"的上市公司发展理念，与 投资者形成良性沟通机制，向资本市场传递公司价值，华润双鹤药业 股份有限公司(以下简称"公司")于 2025 年 4 月 26 日发布了《关于 2024 年度"提质增效重回报"行动方案评估报告及 2025 年度"提质 增效重回报"行动方案的公告》。根据上海证券交易所《关于开展沪 市公司"提质增效重回报"专项行动的倡议》要求，公司应每半年评 估行动方案的执行效果，现将进展情况汇报如下： 一、行动方案执行情况 二、相关措施实施效果说明 (一)提升经营质量 2025 年上半年，公司持续推进"七问"卓越运营体系走深走实， 落实研发创新和外延发展双轮驱动， ...